CARDINAL HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103.2 USD | -0.58% |
|
-4.60% | +2.39% |
| 04-25 | US FDA sends warning to Cardinal Health for marketing unapproved devices | RE |
| 04-24 | Evercore ISI Adjusts Cardinal Health's Price Target to $110 From $118, Keeps In Line Rating | MT |
| Sales 2024 * | 225B 18,025B | Sales 2025 * | 238B 19,060B | Capitalization | 25.1B 2,010B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.21B 96.86B | Net income 2025 * | 1.54B 124B | EV / Sales 2024 * | 0.11 x |
| Net cash position 2024 * | 436M 34.92B | Net cash position 2025 * | 1.34B 108B | EV / Sales 2025 * | 0.1 x |
| P/E ratio 2024 * |
18
x | P/E ratio 2025 * |
15.4
x | Employees | 47,520 |
| Yield 2024 * |
1.96% | Yield 2025 * |
2% | Free-Float | 74.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cardinal Health, Inc.
More recommendations
More press releases
| 1 day | -0.58% | ||
| 1 week | -4.60% | ||
| Current month | -7.77% | ||
| 1 month | -8.29% | ||
| 3 months | -2.36% | ||
| 6 months | +12.93% | ||
| Current year | +2.39% |
1 week
101.23
104.87
1 month
101.23112.37
Current year
100.36116.04
1 year
77.56116.04
3 years
45.85116.04
5 years
39.05116.04
10 years
39.05116.04
| Managers | Title | Age | Since |
|---|---|---|---|
Jason Hollar
CEO | Chief Executive Officer | 51 | 26/04/20 |
Aaron Alt
DFI | Director of Finance/CFO | 53 | 09/02/23 |
Michelle Greene
CTO | Chief Tech/Sci/R&D Officer | 54 | 31/12/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 05/09/22 | |
| Director/Board Member | 71 | 11/09/13 | |
Gregory Kenny
CHM | Chairman | 71 | 31/12/06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 103.2 | -0.58% | 1,399,916 |
| 25/04/24 | 103.8 | +0.26% | 1,642,728 |
| 24/04/24 | 103.5 | +0.16% | 2,057,344 |
| 23/04/24 | 103.4 | +0.53% | 2,477,426 |
| 22/04/24 | 102.8 | -4.95% | 5,287,253 |
Delayed Quote Nyse, April 26, 2024 at 09:00 pm
More quotes
Cardinal Health, Inc. is specialized in the distribution of products and health services to pharmacies, hospitals and medical practices. Net sales break down by activity as follows:
- distribution of pharmaceutical products (92.7%);
- distribution of medical, surgical and laboratory products (7.3%). The group also develops a manufacturing of medical and surgical products activity (masks, overalls, gloves, diagnostic products, products of aspiration and collection of liquids, radiology intervention, respiratory assistance, etc.).
The United States accounts for 97.7% of net sales.
Sector
Pharmaceuticals
Calendar
01/05/2024
- Q3 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
103.2
USD
Average target price
112.4
USD
Spread / Average Target
+8.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.39% | 25.1B | |
| +17.35% | 71.39B | |
| +5.38% | 8.59B | |
| +6.69% | 8.19B | |
| -20.96% | 7.91B | |
| +0.49% | 4.54B | |
| +17.12% | 4.31B | |
| -3.38% | 3.93B | |
| -2.61% | 3.86B | |
| +22.08% | 3.64B |
- Stock Market
- Equities
- CAH Stock
